Regulation of Epstein-Barr virus reactivation from latency

Microbiology and Immunology

Volumn 58, Issue 6, 2014, Pages 307-317

  Murata, Takayuki ^a,b  

^a NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

BZLF1 protein; Epstein Barr virus; Latency; Reactivation

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR; CCAAT ENHANCER BINDING PROTEIN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; HISTONE H3; HISTONE H4; TRANSCRIPTION FACTOR AP 1; VIRUS DNA; BZLF1 PROTEIN, HERPESVIRUS 4, HUMAN; TRANSACTIVATOR PROTEIN;

BZLF1 GENE; CPG ISLAND; DNA METHYLATION; EPIGENETICS; EPSTEIN BARR VIRUS; GENE EXPRESSION REGULATION; GENE INDUCTION; GENE REPRESSION; GENE SILENCING; GENETIC REGULATION; HISTONE ACETYLATION; MOLECULAR DYNAMICS; NONHUMAN; PROGENY; PROMOTER REGION; REVIEW; VIRUS CARCINOGENESIS; VIRUS GENE; VIRUS GENOME; VIRUS LATENCY; VIRUS REACTIVATION; BIOSYNTHESIS; GENETIC TRANSCRIPTION; GENETICS; HUMAN; PHYSIOLOGY; VIRUS ACTIVATION;

GENE EXPRESSION REGULATION, VIRAL; HERPESVIRUS 4, HUMAN; HUMANS; PROMOTER REGIONS, GENETIC; TRANS-ACTIVATORS; TRANSCRIPTION, GENETIC; VIRUS ACTIVATION;

EID: 84901980266     PISSN: 03855600     EISSN: 13480421     Source Type: Journal    
DOI: 10.1111/1348-0421.12155     Document Type: Review

References (111)

1. Young L.S., Murray P.G. ( 2003) Epstein-Barr virus and oncogenesis: from latent genes to tumours. Oncogene 22: 5108-21.
2. Young L.S., Rickinson A.B. ( 2004) Epstein-Barr virus: 40 years on. Nat Rev Cancer 4: 757-68.
3. Amon W., Farrell P.J. ( 2005) Reactivation of Epstein-Barr virus from latency. Rev Med Virol 15: 149-56.
4. Hammerschmidt W., Sugden B. ( 2013) Replication of Epstein-Barr viral DNA. Cold Spring Harb Perspect Biol 5: a013029.
5. Tsurumi T., Fujita M., Kudoh A. ( 2005) Latent and lytic Epstein-Barr virus replication strategies. Rev Med Virol 15: 3-15.
6. Kalla M., Schmeinck A., Bergbauer M., Pich D., Hammerschmidt W. ( 2010) AP-1 homolog BZLF1 of Epstein-Barr virus has two essential functions dependent on the epigenetic state of the viral genome. Proc Natl Acad Sci USA 107: 850-5.
7. Wen W., Iwakiri D., Yamamoto K., Maruo S., Kanda T., Takada K. ( 2007) Epstein-Barr virus BZLF1 gene, a switch from latency to lytic infection, is expressed as an immediate-early gene after primary infection of B lymphocytes. J Virol 81: 1037-42.
8. Murata T., Sato Y., Kimura H. ( 2014) Modes of infection and oncogenesis by the Epstein-Barr virus. Rev Med Virol doi: 10.1002/rmv.1786 [Epub ahead of print].
9. Murata T., Tsurumi T. ( 2013) Epigenetic modification of the Epstein-Barr virus BZLF1 promoter regulates viral reactivation from latency. Front Genet 4: 53.
10. Countryman J., Gradoville L., Bhaduri-McIntosh S., Ye J., Heston L., Himmelfarb S., Shedd D., Miller G. ( 2009) Stimulus duration and response time independently influence the kinetics of lytic cycle reactivation of Epstein-Barr virus. J Virol 83: 10694-709.
11. Miller G., El-Guindy A., Countryman J., Ye J., Gradoville L. ( 2007) Lytic cycle switches of oncogenic human gammaherpesviruses. Adv Cancer Res 97: 81-109.
12. Sugimoto A., Kanda T., Yamashita Y., Murata T., Saito S., Kawashima D., Isomura H., Nishiyama Y., Tsurumi T. ( 2011) Spatiotemporally different DNA repair systems participate in Epstein-Barr virus genome maturation. J Virol 85: 6127-35.
13. Daikoku T., Kudoh A., Fujita M., Sugaya Y., Isomura H., Shirata N., Tsurumi T. ( 2005) Architecture of replication compartments formed during Epstein-Barr virus lytic replication. J Virol 79: 3409-18.
14. Kawashima D., Kanda T., Murata T., Saito S., Sugimoto A., Narita Y., Tsurumi T. ( 2013) Nuclear transport of Epstein-Barr virus DNA polymerase is dependent on the BMRF1 polymerase processivity factor and molecular chaperone Hsp90. J Virol 87: 6482-91.
15. Kudoh A., Fujita M., Kiyono T., Kuzushima K., Sugaya Y., Izuta S., Nishiyama Y., Tsurumi T. ( 2003) Reactivation of lytic replication from B cells latently infected with Epstein-Barr virus occurs with high S-phase cyclin-dependent kinase activity while inhibiting cellular DNA replication. J Virol 77: 851-61.
16. Narita Y., Murata T., Ryo A., Kawashima D., Sugimoto A., Kanda T., Kimura H., Tsurumi T. ( 2013) Pin1 interacts with the Epstein-Barr virus DNA polymerase catalytic subunit and regulates viral DNA replication. J Virol 87: 2120-7.
17. Daikoku T., Kudoh A., Sugaya Y., Iwahori S., Shirata N., Isomura H., Tsurumi T. ( 2006) Postreplicative mismatch repair factors are recruited to Epstein-Barr virus replication compartments. J Biol Chem 281: 11422-30.
18. Kudoh A., Iwahori S., Sato Y., Nakayama S., Isomura H., Murata T., Tsurumi T. ( 2009) Homologous recombinational repair factors are recruited and loaded onto the viral DNA genome in Epstein-Barr virus replication compartments. J Virol 83: 6641-51.
19. Arumugaswami V., Wu T.T., Martinez-Guzman D., Jia Q., Deng H., Reyes N., Sun R. ( 2006) ORF18 is a transfactor that is essential for late gene transcription of a gammaherpesvirus. J Virol 80: 9730-40.
20. Isomura H., Stinski M.F., Murata T., Yamashita Y., Kanda T., Toyokuni S., Tsurumi T. ( 2011) The human cytomegalovirus gene products essential for late viral gene expression assemble into prereplication complexes before viral DNA replication. J Virol 85: 6629-44.
21. Wong E., Wu T.T., Reyes N., Deng H., Sun R. ( 2007) Murine gammaherpesvirus 68 open reading frame 24 is required for late gene expression after DNA replication. J Virol 81: 6761-4.
22. Wong-Ho E., Wu T.T., Davis Z.H., Zhang B., Huang J., Gong H., Deng H., Liu F., Glaunsinger B., Sun R. ( 2014) Unconventional sequence requirement for viral late gene core promoters of murine gammaherpesvirus 68. J Virol 88: 3411-22.
23. Wu T.T., Park T., Kim H., Tran T., Tong L., Martinez-Guzman D., Reyes N., Deng H., Sun R. ( 2009) ORF30 and ORF34 are essential for expression of late genes in murine gammaherpesvirus 68. J Virol 83: 2265-73.
24. Sinclair A.J. ( 2003) BZIP proteins of human gammaherpesviruses. J Gen Virol 84: 1941-9.
25. Speck S.H., Chatila T., Flemington E. ( 1997) Reactivation of Epstein-Barr virus: regulation and function of the BZLF1 gene. Trends Microbiol 5: 399-405.
26. Reinke A.W., Grigoryan G., Keating A.E. ( 2010) Identification of bZIP interaction partners of viral proteins HBZ, MEQ, BZLF1, and K-bZIP using coiled-coil arrays. Biochemistry 49: 1985-97.
27. Adamson A.L., Kenney S. ( 1999) The Epstein-Barr virus BZLF1 protein interacts physically and functionally with the histone acetylase CREB-binding protein. J Virol 73: 6551-8.
28. Zerby D., Chen C.J., Poon E., Lee D., Shiekhattar R., Lieberman P.M. ( 1999) The amino-terminal C/H1 domain of CREB binding protein mediates zta transcriptional activation of latent Epstein-Barr virus. Mol Cell Biol 19: 1617-26.
29. Lieberman P.M., Berk A.J. ( 1991) The Zta trans-activator protein stabilizes TFIID association with promoter DNA by direct protein-protein interaction. Genes Dev 5: 2441-54.
30. Bhende P.M., Seaman W.T., Delecluse H.J., Kenney S.C. ( 2004) The EBV lytic switch protein, Z, preferentially binds to and activates the methylated viral genome. Nat Genet 36: 1099-104.
31. Schepers A., Pich D., Hammerschmidt W. ( 1996) Activation of oriLyt, the lytic origin of DNA replication of Epstein-Barr virus, by BZLF1. Virology 220: 367-76.
32. Fernandez A.F., Rosales C., Lopez-Nieva P., Grana O., Ballestar E., Ropero S., Espada J., Melo S.A., Lujambio A., Fraga M.F., Pino I., Javierre B., Carmona F.J., Acquadro F., Steenbergen R.D., Snijders P.J., Meijer C.J., Pineau P., Dejean A., Lloveras B., Capella G., Quer J., Buti M., Esteban J.I., Allende H., Rodriguez-Frias F., Castellsague X., Minarovits J., Ponce J., Capello D., Gaidano G., Cigudosa J.C., Gomez-Lopez G., Pisano D.G., Valencia A., Piris M.A., Bosch F.X., Cahir-McFarland E., Kieff E., Esteller M. ( 2009) The dynamic DNA methylomes of double-stranded DNA viruses associated with human cancer. Genome Res 19: 438-51.
33. Woellmer A., Arteaga-Salas J.M., Hammerschmidt W. ( 2012) BZLF1 governs CpG-methylated chromatin of Epstein-Barr Virus reversing epigenetic repression. PLoS Pathog 8: e1002902.
34. Countryman J.K., Gradoville L., Miller G. ( 2008) Histone hyperacetylation occurs on promoters of lytic cycle regulatory genes in Epstein-Barr virus-infected cell lines which are refractory to disruption of latency by histone deacetylase inhibitors. J Virol 82: 4706-19.
35. Murata T., Kondo Y., Sugimoto A., Kawashima D., Saito S., Isomura H., Kanda T., Tsurumi T. ( 2012) Epigenetic histone modification of Epstein-Barr virus BZLF1 promoter during latency and reactivation in Raji cells. J Virol 86: 4752-61.
36. Ramasubramanyan S., Osborn K., Flower K., Sinclair A.J. ( 2012) Dynamic chromatin environment of key lytic cycle regulatory regions of the Epstein-Barr virus genome. J Virol 86: 1809-19.
37. Murata T., Narita Y., Sugimoto A., Kawashima D., Kanda T., Tsurumi T. ( 2013) Contribution of myocyte enhancer factor 2 family transcription factors to BZLF1 expression in Epstein-Barr virus reactivation from latency. J Virol 87: 10148-62.
38. Flemington E., Speck S.H. ( 1990) Identification of phorbol ester response elements in the promoter of Epstein-Barr virus putative lytic switch gene BZLF1. J Virol 64: 1217-26.
39. Murata T., Tsurumi T. ( 2013) Switching of EBV cycles between latent and lytic states. Rev Med Virol 24: 142-53.
40. Liu S., Liu P., Borras A., Chatila T., Speck S.H. ( 1997) Cyclosporin A-sensitive induction of the Epstein-Barr virus lytic switch is mediated via a novel pathway involving a MEF2 family member. EMBO J 16: 143-53.
41. Liu S., Borras A.M., Liu P., Suske G., Speck S.H. ( 1997) Binding of the ubiquitous cellular transcription factors Sp1 and Sp3 to the ZI domains in the Epstein-Barr virus lytic switch BZLF1 gene promoter. Virology 228: 11-8.
42. Tsai P.F., Lin S.J., Weng P.L., Tsai S.C., Lin J.H., Chou Y.C., Tsai C.H. ( 2011) Interplay between PKCdelta and Sp1 on histone deacetylase inhibitor-mediated Epstein-Barr virus reactivation. J Virol 85: 2373-85.
43. Ruf I.K., Rawlins D.R. ( 1995) Identification and characterization of ZIIBC, a complex formed by cellular factors and the ZII site of the Epstein-Barr virus BZLF1 promoter. J Virol 69: 7648-57.
44. Wang Y.C., Huang J.M., Montalvo E.A. ( 1997) Characterization of proteins binding to the ZII element in the Epstein-Barr virus BZLF1 promoter: transactivation by ATF1. Virology 227: 323-30.
45. Wu F.Y., Wang S.E., Chen H., Wang L., Hayward S.D., Hayward G.S. ( 2004) CCAAT/enhancer binding protein alpha binds to the Epstein-Barr virus (EBV) ZTA protein through oligomeric interactions and contributes to cooperative transcriptional activation of the ZTA promoter through direct binding to the ZII and ZIIIB motifs during induction of the EBV lytic cycle. J Virol 78: 4847-65.
46. Bhende P.M., Dickerson S.J., Sun X., Feng W.H., Kenney S.C. ( 2007) X-box-binding protein 1 activates lytic Epstein-Barr virus gene expression in combination with protein kinase D. J Virol 81: 7363-70.
47. McDonald C., Karstegl C.E., Kellam P., Farrell P.J. ( 2010) Regulation of the Epstein-Barr virus Zp promoter in B lymphocytes during reactivation from latency. J Gen Virol 91: 622-9.
48. Sun C.C., Thorley-Lawson D.A. ( 2007) Plasma cell-specific transcription factor XBP-1s binds to and transactivates the Epstein-Barr virus BZLF1 promoter. J Virol 81: 13566-77.
49. Iempridee T., Das S., Xu I., Mertz J.E. ( 2011) Transforming growth factor beta-induced reactivation of Epstein-Barr virus involves multiple Smad-binding elements cooperatively activating expression of the latent-lytic switch BZLF1 gene. J Virol 85: 7836-48.
50. Jiang J.H., Wang N., Li A., Liao W.T., Pan Z.G., Mai S.J., Li D.J., Zeng M.S., Wen J.M., Zeng Y.X. ( 2006) Hypoxia can contribute to the induction of the Epstein-Barr virus (EBV) lytic cycle. J Clin Virol 37: 98-103.
51. Iwakiri D., Takada K. ( 2004) Phosphatidylinositol 3-kinase is a determinant of responsiveness to B cell antigen receptor-mediated Epstein-Barr virus activation. J Immunol 172: 1561-6.
52. Flemington E., Speck S.H. ( 1990) Autoregulation of Epstein-Barr virus putative lytic switch gene BZLF1. J Virol 64: 1227-32.
53. Yin Q., Jupiter K., Flemington E.K. ( 2004) The Epstein-Barr virus transactivator Zta binds to its own promoter and is required for full promoter activity during anti-Ig and TGF-beta1 mediated reactivation. Virology 327: 134-43.
54. Chen C.C., Yang Y.C., Wang W.H., Chen C.S., Chang L.K. ( 2011) Enhancement of Zta-activated lytic transcription of Epstein-Barr virus by Ku80. J Gen Virol 92: 661-8.
55. Murata T., Sato Y., Nakayama S., Kudoh A., Iwahori S., Isomura H., Tajima M., Hishiki T., Ohshima T., Hijikata M., Shimotohno K., Tsurumi T. ( 2009) TORC2, a coactivator of cAMP-response element-binding protein, promotes Epstein-Barr virus reactivation from latency through interaction with viral BZLF1 protein. J Biol Chem 284: 8033-41.
56. Kraus R.J., Mirocha S.J., Stephany H.M., Puchalski J.R., Mertz J.E. ( 2001) Identification of a novel element involved in regulation of the lytic switch BZLF1 gene promoter of Epstein-Barr virus. J Virol 75: 867-77.
57. Kraus R.J., Perrigoue J.G., Mertz J.E. ( 2003) ZEB negatively regulates the lytic-switch BZLF1 gene promoter of Epstein-Barr virus. J Virol 77: 199-207.
58. Yu X., Wang Z., Mertz J.E. ( 2007) ZEB1 regulates the latent-lytic switch in infection by Epstein-Barr virus. PLoS Pathog 3: e194.
59. Ellis A.L., Wang Z., Yu X., Mertz J.E. ( 2010) Either ZEB1 or ZEB2/SIP1 can play a central role in regulating the Epstein-Barr virus latent-lytic switch in a cell-type-specific manner. J Virol 84: 6139-52.
60. Murata T., Noda C., Saito S., Kawashima D., Sugimoto A., Isomura H., Kanda T., Yokoyama K.K., Tsurumi T. ( 2011) Involvement of Jun dimerization protein 2 (JDP2) in the maintenance of Epstein-Barr virus latency. J Biol Chem 286: 22007-16.
61. Liu P., Liu S., Speck S.H. ( 1998) Identification of a negative cis element within the ZII domain of the Epstein-Barr virus lytic switch BZLF1 gene promoter. J Virol 72: 8230-9.
62. Yu X., McCarthy P.J., Lim H.J., Iempridee T., Kraus R.J., Gorlen D.A., Mertz J.E. ( 2011) The ZIIR element of the Epstein-Barr virus BZLF1 promoter plays a central role in establishment and maintenance of viral latency. J Virol 85: 5081-90.
63. Montalvo E.A., Cottam M., Hill S., Wang Y.J. ( 1995) YY1 binds to and regulates cis-acting negative elements in the Epstein-Barr virus BZLF1 promoter. J Virol 69: 4158-65.
64. Zhang Q., Wang Y.C., Montalvo E.A. ( 1999) Smubp-2 represses the Epstein-Barr virus lytic switch promoter. Virology 255: 160-70.
65. Thomas C., Dankesreiter A., Wolf H., Schwarzmann F. ( 2003) The BZLF1 promoter of Epstein-Barr virus is controlled by E box-/HI-motif-binding factors during virus latency. J Gen Virol 84: 959-64.
66. Niller H.H., Salamon D., Uhlig J., Ranf S., Granz M., Schwarzmann F., Wolf H., Minarovits J. ( 2002) Nucleoprotein structure of immediate-early promoters Zp and Rp and of oriLyt of latent Epstein-Barr virus genomes. J Virol 76: 4113-8.
67. Mannick J.B., Asano K., Izumi K., Kieff E., Stamler J.S. ( 1994) Nitric oxide produced by human B lymphocytes inhibits apoptosis and Epstein-Barr virus reactivation. Cell 79: 1137-46.
68. Gao X., Tajima M., Sairenji T. ( 1999) Nitric oxide down-regulates Epstein-Barr virus reactivation in epithelial cell lines. Virology 258: 375-81.
69. Murata T., Hotta N., Toyama S., Nakayama S., Chiba S., Isomura H., Ohshima T., Kanda T., Tsurumi T. ( 2010) Transcriptional repression by sumoylation of Epstein-Barr virus BZLF1 protein correlates with association of histone deacetylase. J Biol Chem 285: 23925-35.
70. Sista N.D., Barry C., Sampson K., Pagano J. ( 1995) Physical and functional interaction of the Epstein-Barr virus BZLF1 transactivator with the retinoic acid receptors RAR alpha and RXR alpha. Nucleic Acids Res 23: 1729-36.
71. Sista N.D., Pagano J.S., Liao W., Kenney S. ( 1993) Retinoic acid is a negative regulator of the Epstein-Barr virus protein (BZLF1) that mediates disruption of latent infection. Proc Natl Acad Sci USA 90: 3894-8.
72. Gutsch D.E., Holley-Guthrie E.A., Zhang Q., Stein B., Blanar M.A., Baldwin A.S., Kenney S.C. ( 1994) The bZIP transactivator of Epstein-Barr virus, BZLF1, functionally and physically interacts with the p65 subunit of NF-kappa B. Mol Cell Biol 14: 1939-48.
73. Robinson A.R., Kwek S.S., Kenney S.C. ( 2012) The B-cell specific transcription factor, Oct-2, promotes Epstein-Barr virus latency by inhibiting the viral immediate-early protein, BZLF1. PLoS Pathog 8: e1002516.
74. Raver R.M., Panfil A.R., Hagemeier S.R., Kenney S.C. ( 2013) The B-cell-specific transcription factor and master regulator Pax5 promotes Epstein-Barr virus latency by negatively regulating the viral immediate early protein BZLF1. J Virol 87: 8053-63.
75. Brown H.J., Song M.J., Deng H., Wu T.T., Cheng G., Sun R. ( 2003) NF-kappaB inhibits gammaherpesvirus lytic replication. J Virol 77: 8532-40.
76. Li Y., Zhang Y., Fu M., Yao Q., Zhuo H., Lu Q., Niu X., Zhang P., Pei Y., Zhang K. ( 2012) Parthenolide induces apoptosis and lytic cytotoxicity in Epstein-Barr virus-positive Burkitt lymphoma. Mol Med Rep 6: 477-82.
77. Liu S.F., Wang H., Lin X.C., Xiang H., Deng X.Y., Li W., Tang M., Cao Y. ( 2008) NF-kappaB inhibitors induce lytic cytotoxicity in Epstein-Barr virus-positive nasopharyngeal carcinoma cells. Cell Biol Int 32: 1006-13.
78. Saito S., Murata T., Kanda T., Isomura H., Narita Y., Sugimoto A., Kawashima D., Tsurumi T. ( 2013) Epstein-Barr virus deubiquitinase downregulates TRAF6-mediated NF-kappaB signaling during productive replication. J Virol 87: 4060-70.
79. Konforte D., Paige C.J. ( 2009) Interleukin-21 regulates expression of the immediate-early lytic cycle genes and proteins in Epstein-Barr Virus infected B cells. Virus Res 144: 339-43.
80. Daigle D., Megyola C., El-Guindy A., Gradoville L., Tuck D., Miller G., Bhaduri-McIntosh S. ( 2010) Upregulation of STAT3 marks Burkitt lymphoma cells refractory to Epstein-Barr virus lytic cycle induction by HDAC inhibitors. J Virol 84: 993-1004.
81. Chen H., Hutt-Fletcher L., Cao L., Hayward S.D. ( 2003) A positive autoregulatory loop of LMP1 expression and STAT activation in epithelial cells latently infected with Epstein-Barr virus. J Virol 77: 4139-48.
82. Chen H., Lee J.M., Zong Y., Borowitz M., Ng M.H., Ambinder R.F., Hayward S.D. ( 2001) Linkage between STAT regulation and Epstein-Barr virus gene expression in tumors. J Virol 75: 2929-37.
83. Johansson P., Jansson A., Ruetschi U., Rymo L. ( 2009) Nuclear factor-kappaB binds to the Epstein-Barr virus LMP1 promoter and upregulates its expression. J Virol 83: 1393-401.
84. Kis L.L., Salamon D., Persson E.K., Nagy N., Scheeren F.A., Spits H., Klein G., Klein E. ( 2010) IL-21 imposes a type II EBV gene expression on type III and type I B cells by the repression of C- and activation of LMP-1-promoter. Proc Natl Acad Sci USA 107: 872-7.
85. Kis L.L., Takahara M., Nagy N., Klein G., Klein E. ( 2006) IL-10 can induce the expression of EBV-encoded latent membrane protein-1 (LMP-1) in the absence of EBNA-2 in B lymphocytes and in Burkitt lymphoma- and NK lymphoma-derived cell lines. Blood 107: 2928-35.
86. Eliopoulos A.G., Young L.S. ( 2001) LMP1 structure and signal transduction. Semin Cancer Biol 11: 435-44.
87. Gires O., Kohlhuber F., Kilger E., Baumann M., Kieser A., Kaiser C., Zeidler R., Scheffer B., Ueffing M., Hammerschmidt W. ( 1999) Latent membrane protein 1 of Epstein-Barr virus interacts with JAK3 and activates STAT proteins. EMBO J 18: 3064-73.
88. Huen D.S., Henderson S.A., Croom-Carter D., Rowe M. ( 1995) The Epstein-Barr virus latent membrane protein-1 (LMP1) mediates activation of NF-kappa B and cell surface phenotype via two effector regions in its carboxy-terminal cytoplasmic domain. Oncogene 10: 549-60.
89. Paine E., Scheinman R.I., Baldwin A.S., Jr., Raab-Traub N. ( 1995) Expression of LMP1 in epithelial cells leads to the activation of a select subset of NF-kappa B/Rel family proteins. J Virol 69: 4572-6.
90. Tsao S.W., Tramoutanis G., Dawson C.W., Lo A.K., Huang D.P. ( 2002) The significance of LMP1 expression in nasopharyngeal carcinoma. Semin Cancer Biol 12: 473-87.
91. Prince S., Keating S., Fielding C., Brennan P., Floettmann E., Rowe M. ( 2003) Latent membrane protein 1 inhibits Epstein-Barr virus lytic cycle induction and progress via different mechanisms. J Virol 77: 5000-7.
92. Murata T., Iwata S., Siddiquey M.N., Kanazawa T., Goshima F., Kawashima D., Kimura H., Tsurumi T. ( 2013) Heat shock protein 90 inhibitors repress latent membrane protein 1 (LMP1) expression and proliferation of Epstein-Barr virus-positive natural killer cell lymphoma. PLoS One 8: e63566.
93. Gao X., Ikuta K., Tajima M., Sairenji T. ( 2001) 12-O-tetradecanoylphorbol-13-acetate induces Epstein-Barr virus reactivation via NF-kappaB and AP-1 as regulated by protein kinase C and mitogen-activated protein kinase. Virology 286: 91-9.
94. Goswami R., Gershburg S., Satorius A., Gershburg E. ( 2012) Protein kinase inhibitors that inhibit induction of lytic program and replication of Epstein-Barr virus. Antiviral Res 96: 296-304.
95. Nanbo A., Terada H., Kachi K., Takada K., Matsuda T. ( 2012) Roles of cell signaling pathways in cell-to-cell contact-mediated Epstein-Barr virus transmission. J Virol 86: 9285-96.
96. Katsumura K.R., Maruo S., Takada K. ( 2012) EBV lytic infection enhances transformation of B-lymphocytes infected with EBV in the presence of T-lymphocytes. J Med Virol 84: 504-10.
97. Ma S.D., Hegde S., Young K.H., Sullivan R., Rajesh D., Zhou Y., Jankowska-Gan E., Burlingham W.J., Sun X., Gulley M.L., Tang W., Gumperz J.E., Kenney S.C. ( 2011) A new model of Epstein-Barr virus infection reveals an important role for early lytic viral protein expression in the development of lymphomas. J Virol 85: 165-77.
98. Hsu M., Wu S.Y., Chang S.S., Su I.J., Tsai C.H., Lai S.J., Shiau A.L., Takada K., Chang Y. ( 2008) Epstein-Barr virus lytic transactivator Zta enhances chemotactic activity through induction of interleukin-8 in nasopharyngeal carcinoma cells. J Virol 82: 3679-88.
99. Bejarano M.T., Masucci M.G. ( 1998) Interleukin-10 abrogates the inhibition of Epstein-Barr virus-induced B-cell transformation by memory T-cell responses. Blood 92: 4256-62.
100. Cayrol C., Flemington E.K. ( 1995) Identification of cellular target genes of the Epstein-Barr virus transactivator Zta: activation of transforming growth factor beta igh3 (TGF-beta igh3) and TGF-beta 1. J Virol 69: 4206-12.
101. Hong G.K., Kumar P., Wang L., Damania B., Gulley M.L., Delecluse H.J., Polverini P.J., Kenney S.C. ( 2005) Epstein-Barr virus lytic infection is required for efficient production of the angiogenesis factor vascular endothelial growth factor in lymphoblastoid cell lines. J Virol 79: 13984-92.
102. Hoebe E.K., Le Large T.Y., Tarbouriech N., Oosterhoff D., De Gruijl T.D., Middeldorp J.M., Greijer A.E. ( 2012) Epstein-Barr virus-encoded BARF1 protein is a decoy receptor for macrophage colony stimulating factor and interferes with macrophage differentiation and activation. Viral Immunol 25: 461-70.
103. Kudoh A., Fujita M., Zhang L., Shirata N., Daikoku T., Sugaya Y., Isomura H., Nishiyama Y., Tsurumi T. ( 2005) Epstein-Barr virus lytic replication elicits ATM checkpoint signal transduction while providing an S-phase-like cellular environment. J Biol Chem 280: 8156-63.
104. Sinclair A., Yarranton S., Schelcher C. ( 2006) DNA-damage response pathways triggered by viral replication. Expert Rev Mol Med 8: 1-11.
105. Sato Y., Tsurumi T. ( 2013) Genome guardian p53 and viral infections. Rev Med Virol 23: 213-20.
106. Tarakanova V.L., Leung-Pineda V., Hwang S., Yang C.W., Matatall K., Basson M., Sun R., Piwnica-Worms H., Sleckman B.P., Virgin H.W.T. ( 2007) Gamma-herpesvirus kinase actively initiates a DNA damage response by inducing phosphorylation of H2AX to foster viral replication. Cell Host Microbe 1: 275-86.
107. Chang Y.H., Lee C.P., Su M.T., Wang J.T., Chen J.Y., Lin S.F., Tsai C.H., Hsieh M.J., Takada K., Chen M.R. ( 2012) Epstein-Barr virus BGLF4 kinase retards cellular S-phase progression and induces chromosomal abnormality. PLoS One 7: e39217.
108. Wu C.C., Liu M.T., Chang Y.T., Fang C.Y., Chou S.P., Liao H.W., Kuo K.L., Hsu S.L., Chen Y.R., Wang P.W., Chen Y.L., Chuang H.Y., Lee C.H., Chen M., Wayne Chang W.S., Chen J.Y. ( 2010) Epstein-Barr virus DNase (BGLF5) induces genomic instability in human epithelial cells. Nucleic Acids Res 38: 1932-49.
109. Ma S.D., Yu X., Mertz J.E., Gumperz J.E., Reinheim E., Zhou Y., Tang W., Burlingham W.J., Gulley M.L., Kenney S.C. ( 2012) An Epstein-Barr Virus (EBV) mutant with enhanced BZLF1 expression causes lymphomas with abortive lytic EBV infection in a humanized mouse model. J Virol 86: 7976-87.
110. Feng W.H., Hong G., Delecluse H.J., Kenney S.C. ( 2004) Lytic induction therapy for Epstein-Barr virus-positive B-cell lymphomas. J Virol 78: 1893-902.
111. Perrine S.P., Hermine O., Small T., Suarez F., O'Reilly R., Boulad F., Fingeroth J., Askin M., Levy A., Mentzer S.J., Di Nicola M., Gianni A.M., Klein C., Horwitz S., Faller D.V. ( 2007) A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies. Blood 109: 2571-8.